Evidence map›Paper›PMID 26831335›Full record

Trial reportBMC neuroscience2016

Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.

Massiva Sayad, Mohamed Zouambia, Malika Chaouch, Farida Ferrat, Mustapha Nebbal, Mohamed Bendini, Suzanne Lesage, Alexis Brice, Mohamed Brahim Errahmani, Boualem Asselah

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Deep brain stimulation for Parkinson's disease.Journal of internal medicine · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Gender Differences and Quality of Life in Parkinson's Disease.International journal of environmental research and public health · 2020
    Review
  16. Therapy of Parkinson's Disease Subtypes.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Massiva SayadLaboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. sayad_massiva@yahoo.fr.
Mohamed ZouambiaLaboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. zouambia26@gmail.com.
Malika ChaouchDepartment of Neurology, CHU Ben Aknoun, 16000, Algiers, Algeria. chaouch_malika@hotmail.com.
Farida FerratDepartment of Neurology, CHU Ben Aknoun, 16000, Algiers, Algeria. ferratfarida@yahoo.fr.
Mustapha NebbalDepartment of Neurosurgery, Mohamed-Seghir Nekkache Military Hospital, Djasr Kasentina, Algiers, Algeria. mus.neuro@gmail.com.
Mohamed BendiniDepartment of Neurology, Mohamed-Seghir Nekkache Military Hospital, Djasr Kasentina, Algiers, Algeria. m-bendini@hotmail.fr.
Suzanne LesageUMR S 1127 PaInserm U 1127, Sorbonne University, UPMC Univ Paris 06, Paris, France. suzanne.lesage@upmc.fr.
Alexis BriceUMR S 1127 PaInserm U 1127, Sorbonne University, UPMC Univ Paris 06, Paris, France. alexis.brice@upmc.fr.
Mohamed Brahim ErrahmaniDepartment of Chemistry, Blida 1 University, BP 270, 09000, Blida, Algeria. m.brahim.errahmani@univ-blida.dz.
Boualem AsselahLaboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. asselah.boualem@gmail.com.
University of Sciences and Technology Houari Boumediene · DZCentre Hospitalo-Universitaire Bab El Oued · DZInserm · FRUniversity of Blida · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson's disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been suggested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors' native Algeria) on the symptom response of PD in patients who underwent STN-DBS.

methodsWe carried out a comparative statistical study for the clinical evaluation and neuropsychological assessment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple correspondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with similar modalities.

resultsThe MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Parkin mutations who had a different "honeymoon" period and different initial symptoms. The results showed considerable improvement of motor unified parkinson's disease rating scale III (UPDRS-III) in a situation of stimulation without medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the NC patients (25.5 %). The same result was observed for the Schwab and England's activities of daily living scale (S and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before they underwent surgery.

conclusionsThis study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC than on idiopathic patients.

Indexed as

Deep Brain StimulationMutationFemaleHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedParkinson DiseaseProtein Serine-Threonine KinasesSubthalamic NucleusTreatment OutcomeLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Serine-Threonine Kinases

Identifiers

PMID26831335
PMCPMC4736184
OpenAlexW2265056599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.